Chief Commercial Officer · INTERCEPT PHARMACEUTICALS, INC. (ICPT)

Linda Richardson

FY2022 is the first fiscal year CompBrief holds for Linda Richardson as a named executive officer of INTERCEPT PHARMACEUTICALS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,336,829

Salary $496,500Stock awards $344,329

4th of 5 named executive officers at Intercept Pharmaceuticals by FY2022 total.

5 named officers on file for INTERCEPT PHARMACEUTICALS, FY2022

Linda Richardson’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 3 equity grants, each cited to its filing
  • ICPT’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how INTERCEPT PHARMACEUTICALS’s whole pay program stands against its peers

  • INTERCEPT PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ICPT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 1, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Linda Richardson’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Linda Richardson compensation by year

INTERCEPT PHARMACEUTICALS Summary Compensation Table · the one fiscal year held
In US dollars, as INTERCEPT PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$496,500
Bonus$0
Stock awards$344,329
Option awards$154,770
Non-equity incentive$324,255
Pension and deferred compensation$0
All other$16,975
Total$1,336,829

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: INTERCEPT PHARMACEUTICALS, INC. DEF 14A filed May 1, 2023, accession 0001104659-23-053540, and prior-year filings.

How this page was built: the INTERCEPT PHARMACEUTICALS, INC. filed document, accession 0001104659-23-053540. Every figure is read from that document and cited to the page and table it appears in. Filed May 1, 2023.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU7,725$95,558—
PSU5,150$63,706—
PSU4,600$56,902—
RSU4,149$51,323—
RSU2,985$36,924—
RSU909$11,244—
Option1,474—$99.66
Option4,750—$29.46
Option4,605—$31.32
Option13,200—$14.44

Per the Outstanding Equity Awards at Fiscal Year-End table in INTERCEPT PHARMACEUTICALS, INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

10 Form 4 lines since the FY2022 proxy (filed May 1, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2023-11-08Disposition to the issuer derivative—5,896—0
2023-11-08Disposition to the issuer derivative—9,500—0
2023-11-08Disposition to the issuer derivative—17,600—0
2023-11-08Disposition to the issuer derivative—8,368—0
2023-11-08Disposition to the issuer derivative—5,000—0
2023-11-08U—16,706$19.000
2023-11-08Disposition to the issuer—26,585$19.000
2023-11-08Disposition to the issuer derivative—20,000—0

The 8 most recent of 10 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Change-in-control & termination

estimated payments INTERCEPT PHARMACEUTICALS discloses, by trigger · FY2022
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Change in control, no termination—$313,390—$313,390
Death$0$190,340$0$190,340
Resignation for good reason, no change in control$498,000$116,389$11,871$626,260
Involuntary termination without cause$498,000$116,389$11,871$626,260
Disability$0$190,340$0$190,340
Change in control and involuntary termination$498,000$313,390$11,871$823,261

Per the Potential Payments Upon Termination or Change in Control table in INTERCEPT PHARMACEUTICALS, INC.'s FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.

INTERCEPT PHARMACEUTICALS’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Jerome DursoPresident & CEO$4,455,463
Michelle BerreyPresident of R&D and Chief Medical Officer$1,614,245
Andrew SaikCFO$1,387,699
Linda Richardson · this pageChief Commercial Officer$1,336,829
Jared FreedbergGeneral Counsel$1,311,653

The full INTERCEPT PHARMACEUTICALS compensation record

free company brief

This page is one person within INTERCEPT PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the INTERCEPT PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are INTERCEPT PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Linda Richardson's compensation dossier · One-time report. No refunds.